Next-generation peptide vaccines for advanced cancer (Q38056246)

27 August 2017

title

Next-generation peptide vaccines for advanced cancer (English)

1 reference

27 August 2017

Akira Yamada

1

1 reference

27 August 2017

Tetsuro Sasada

series ordinal

2

1 reference

27 August 2017

Masanori Noguchi

series ordinal

3

1 reference

27 August 2017

Kyogo Itoh

series ordinal

4

1 reference

27 August 2017

publication date

4 December 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

104

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

15-21

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

27 August 2017

cites work

1 reference

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

21 January 2018

1 reference

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer

21 January 2018

1 reference

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial

21 January 2018

1 reference

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.

21 January 2018

1 reference

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

21 January 2018

1 reference

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

21 January 2018

1 reference

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

21 January 2018

1 reference

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine

21 January 2018

1 reference

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

21 January 2018

1 reference

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer

21 January 2018

1 reference

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.

21 January 2018

1 reference

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.

21 January 2018

1 reference

Personalized peptide vaccines: a new therapeutic modality for cancer

21 January 2018

1 reference

Recent advances in cancer vaccines: an overview

21 January 2018

1 reference

Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery

21 January 2018

1 reference

Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide

21 January 2018

1 reference

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

21 January 2018

1 reference

Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer

21 January 2018

1 reference

A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients

21 January 2018

1 reference

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.

21 January 2018

1 reference

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

21 January 2018

1 reference

Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer

21 January 2018

1 reference

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

21 January 2018

1 reference

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.

21 January 2018

1 reference

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy

21 January 2018

1 reference

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides

21 January 2018

1 reference

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

21 January 2018

1 reference

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

21 January 2018

1 reference

Personalized peptide vaccination in patients with refractory non-small cell lung cancer.

21 January 2018

1 reference

12 December 2020

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer

1 reference

12 December 2020

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen

1 reference

12 December 2020

Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment

1 reference

12 December 2020

Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients

1 reference

12 December 2020

Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients

1 reference

12 December 2020

A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin

1 reference

12 December 2020

Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer

1 reference

12 December 2020

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer

1 reference

12 December 2020

Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine

1 reference

12 December 2020

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer

1 reference

12 December 2020

Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients

1 reference

12 December 2020

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine

1 reference

12 December 2020

Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers

1 reference

12 December 2020

Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer

1 reference

12 December 2020

Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer

1 reference

12 December 2020

Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers

1 reference

12 December 2020

Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients

1 reference

12 December 2020

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

1 reference

12 December 2020

A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low‐dose estramustine in HLA‐A24‐positive patients with castration‐resistant prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1111/CAS.12050

1 reference

27 August 2017

1 reference